Advertisement
Advertisement

CRNX

CRNX logo

Crinetics Pharmaceuticals, Inc.

83.85
USD
Sponsored
+0.12
+0.14%
Jul 27, 15:59 UTC -4
Closed
exchange

After-Market

83.48

-0.37
-0.44%

CRNX Earnings Reports

Positive Surprise Ratio

CRNX beat 9 of 32 last estimates.

28%

Next Report

Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$15.14M
/
-$1.23
Implied change from Q1 26 (Revenue/ EPS)
+41.02%
/
--
Implied change from Q2 25 (Revenue/ EPS)
+1368.17%
/
--

Crinetics Pharmaceuticals, Inc. earnings per share and revenue

On May 07, 2026, CRNX reported earnings of -1.23 USD per share (EPS) for Q1 26, beating the estimate of -1.26 USD, resulting in a 2.51% surprise. Revenue reached 10.73 million, compared to an expected 8.68 million, with a 23.64% difference. The market reacted with a -13.82% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of -1.23 USD, with revenue projected to reach 15.14 million USD, implying an increase of 0.00% EPS, and increase of 41.02% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Summit Therapeutics Inc. Common Stock
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.28
Actual
-$0.28
Surprise
+1.72%
logo
Champions Oncology, Inc.
Report Date
Jul 27, 2026 For Q4 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+1.96%
FAQ
For Q1 2026, Crinetics Pharmaceuticals, Inc. reported EPS of -$1.23, beating estimates by 2.51%, and revenue of $10.73M, 23.64% above expectations.
The stock price moved down -13.82%, changed from $43.49 before the earnings release to $37.48 the day after.
The next earning report is scheduled for Aug 04, 2026.
Based on 12 analysts, Crinetics Pharmaceuticals, Inc. is expected to report EPS of -$1.23 and revenue of $15.14M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement